Edison Oncology and Apollomics Announce Treatment of First Patient with EO1001 (APL-122) in a Phase I/IIa Clinical Trial

MENLO PARK, CA and HELSINKI, FINLAND, Oct 1, 2021 - (ACN Newswire via SEAPRWire.com) - Edison Oncology Holding Corp. ("Edison Oncology"), a company established to develop new therapies targeting the fight against cancer, and Apollomics Inc. ("Apollomics"), an innovative biopharmaceutical company committed to the discovery and development of mono- and...

Robotic device helps remove tumours in throats

Two local universities have jointly developed what researchers describe as a groundbreaking robotic device to treat head and neck cancer, which is said to be less invasive than traditional forms of treatment and spare patients from remaining in "extreme" body positions during surgery. Medical and engineering experts from Chinese University...

Eisai’s Anti-Epileptic Drug Fycompa Approved In China As Monotherapy For Partial-Onset Seizures And Pediatric Indication For Partial-Onset Seizures

TOKYO, Aug 2, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) has obtained two additional approvals as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for pediatric indication for...

Vaccinated elderly man among latest Covid-19 patients

Health authorities recorded two imported Covid-19 infections on Sunday, involving a 75-year-old man who flew in from the United States and a 25-year-old woman who arrived from Bangladesh. The 75-year-old had both doses of the Pfizer-BioNTech vaccine in the US, receiving the shots in April and May. He was asymptomatic...

ACT Genomics Completes Acquisition of MC Diagnostics

HONG KONG, Jul 6, 2021 - (ACN Newswire via SEAPRWire.com) - ACT Genomics Co. Ltd. ("ACT Genomics" or "the Group") has completed the acquisition of MC Diagnostics Ltd. ("MCD"), a specialist molecular diagnostic company based in the United Kingdom, which marks the Group's entry into the European precision medicine market.MCD...

Long-stay hospital patients to get Covid jabs

The Hospital Authority said on Monday that it has started vaccinating its long-stay psychiatric patients against Covid-19. The authority’s chief executive Tony Ko said he believed a majority of them were suitable to receive the shots. Speaking on an RTHK programme, he said other long-term in-patients, such as those undergoing...

Vaccination assessment service offer for HA patients

Patients registered with the Hospital Authority (HA) can make an appointment to be assessed for their suitability for Covid-19 vaccination starting from June 25, rather than having to wait for their next routine appointment. Patients will be able to book two to three days in advance, by calling the general...

FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease

TOKYO, Jun 8, 2021 - (JCN Newswire via SEAPRWire.com) - Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM (aducanumab-avwa) as the first and only Alzheimer's disease treatment to address a defining pathology of...

Only a quarter of the unvaccinated want jabs: CUHK

Only one in four Hongkongers who are yet to receive a Covid jab plan to get vaccinated within the next six months, researchers at Chinese University said on Thursday. Around 1,047,000 of the territory's 7.5 million people have had two doses of vaccine since the inoculation programme began more than...

Patients recovered from Covid need only 1 jab: govt

The government said patients who have recovered from Covid-19 will be regarded as having completed the vaccination course two weeks after they've received the first dose. It said on Friday that a special arrangement will be made to reflect their condition on vaccination records. In a statement, the government said...

Anticancer Agent “Remitoro Intravenous Drip Infusion 300 microgram” (Denileukin Diftitox (Genetical Recombination)) Launched in Japan

Tokyo, May 19, 2021 - (JCN Newswire via SEAPRWire.com) - Eisai Co., Ltd. announced today that it has launched the anticancer agent "Remitoro® for Intravenous Drip Infusion 300μg" (Denileukin Diftitox (Genetical Recombination)) with the indications of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma...